title: Response to Letter to the Editor Regarding OpT2mise Study.
authors.affiliation: 1 Diabetes Unit, Endocrinology and Nutrition Department, University Hospital Clinic , Barcelona, Spain .
authors.forename: Ignacio
authors.initials: I
authors.lastname: Conget
authors.affiliation: 2 LMC Diabetes & Endocrinology , Toronto, Ontario, Canada .
authors.forename: Ronnie
authors.initials: R
authors.lastname: Aronson
authors.forename: Ohad
authors.initials: O
authors.lastname: Cohen
authors.affiliation: 4 Department of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center , Caen, France .
authors.forename: Yves
authors.initials: Y
authors.lastname: Reznik
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D016903:Drug Monitoring; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D007333:Insulin Resistance; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D018843:Republic of North Macedonia
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin